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The aim of this work is to present the two one-sided test (TOST) as an alternative approach to compare 
dissolution profiles of extended-release dosage forms. The dissolution profiles of oxycodone extended-
release tablets containing 10 mg, 20 mg and 40 mg (reference and generic) were evaluated according to 
the requirements described in United States Pharmacopeia. These dissolution profiles were compared 
using the conventional similarity factor (f2) and the proposed TOST as an equivalence test. TOST is 
a simple and alternative approach to compare dissolution profiles of extended-release dosage forms. 
It allows us to identify the time-point (or time-points) that did not show similarity. We concluded that 
the two one-sided test performed at a significance level of 5% and defined as D = 10 showed results 
comparable to those obtained by the conventional similarity factor (f2).
Uniterms: Dissolution profile. Extended-release tablets. Similarity factor. Two one-sided test. Equivalence 
test.
O objetivo deste trabalho é apresentar o teste uni-caudal duplo (TOST) como uma abordagem alternativa 
na comparação do perfil de dissolução de formas farmacêuticas de liberação prolongada. Os perfis de 
dissolução de comprimidos de liberação prolongada de oxicodona contendo 10 mg, 20 mg e 40 mg 
(genérico e referência) foram avaliados de acordo com os requisitos descritos na Farmacopeia Americana. 
Estes perfis de dissolução foram comparados empregando-se o fator de semelhança convencional (f2) 
e o método TOST como teste de equivalência. TOST é uma abordagem simples e alternativa para a 
comparação de perfis de dissolução de formas farmacêuticas de liberação prolongada. Este permite 
identificar o ponto (ou pontos) que não apresentou semelhança. Considerando-se D = 10, concluímos 
que o teste uni-caudal duplo num nível de significância de 5% apresenta resultados comparáveis àqueles 
obtidos com o fator de semelhança convencional (f2).
Unitermos: Perfil de dissolução. Comprimidos de liberação prolongada. Fator de semelhança. Test 
uni-caudal duplo. Teste de equivalência.
INTRODUCTION
The absorption of a solid dosage form after oral 
administration depends on three factors: the release of 
the substance taken, the dissolution of the drug under 
physiological conditions and the permeability across the 
gastrointestinal tract. Due to the critical nature of the first 
two of these steps, an in vitro dissolution may be relevant 
to the prediction of an in vivo performance (Amidon et al., 
1995; FDA, 1997; Siewert et al.; 2003).
Dissolution studies can, among other useful 
purposes, be used as tools in the control of quality to 
demonstrate consistency in manufacture as well as 
similarity between different products/formulations. The 
dissolution profile comparison may be carried out using 
model independent or model dependent methods (EMEA, 
2001).
An extended-release dosage form requires at least 
three test time points to characterize the in vitro drug 
release profile. An early time point, usually consisting of 
1 to 2 hours, is used to show that there is little probability 
of dose dumping; an intermediate time point is chosen 
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to define the in vitro release profile of the dosage form; 
a final time point is related to the complete release of the 
drug. Test times and specifications are usually established 
taking the evaluation of drug release profile data as a basis 
(USP 35, 2012a).
A simple model independent approach used a 
difference factor (f1) and a similarity factor (f2) to compare 
dissolution profiles (Moore, Flanner, 1996). The difference 
factor (f1) calculates the percentage (%) of difference 
between the two curves at each time point, there being 
a measurement of relative error between the two curves. 
The similarity factor (f2) is a logarithmic reciprocal square 
root transformation of the sum of squared error and works 
as a measurement of the similarity in the dissolution 
percentage between the two curves (FDA, 1997).
This model independent method becomes the most 
suitable for dissolution profile comparison when the 
following recommendations are taken into account: (a) 
five or more dissolution time points must be available; 
(b) dissolution measurements of the test and reference 
batches must be made under the same conditions; (c) 
only one measurement must be considered after an 85% 
dissolution of both products; (d) the use of a mean will 
only be possible if the relative standard deviation (RSD) 
at the earlier time points is not superior to 20% and to 10% 
at other time points (FDA, 1997; O’Hara et al., 1998; Shah 
et al., 1998). An f2 value between 50 and 100 generally 
suggests similarity between the two dissolution profiles.
Studies carried out by several  researchers 
demonstrated that the similarity factor (f2) is a useful 
tool to confirm similarity between two dissolution profiles. 
However, according to our practical experience, similarity 
factor f2 does not allow point-to-point comparison, 
occasionally not showing which time-point (or time-
points) is not similar. These limitations are critical, 
particularly regarding extended-release dosage forms.
The aim of this work is to present the two one-
sided test (TOST) as an alternative approach to compare 
dissolution profiles of extended-release dosage forms. 
Similarity factor f2 and two one-sided test (TOST) were 
compared, taking the results of dissolution profiles of 
oxycodone extended-release tablets as a basis. The two 
one-sided test has been employed in the assessment of 
pharmaceutical equivalence (Lourenço, Pinto, 2012).
MATERIAL AND METHODS
Extended-Release Tablets and Reference Standard
Oxycodone extended-release tablets of 10 mg, 20 
mg and 40 mg (reference and generic) were purchased 
from Brazilian suppliers. Oxycodone hydrochloride 
reference standard (Batch: KOG276, Potency: 99.6%) was 
provided by United States Pharmacopeia.
Instrumentation
The dissolution tests were conducted using a 
VanKel system (VanKel VK 7010) ̶ comprising a bath 
with six vessels ̶ and meeting the physical and mechanical 
specifications required by the USP chapter <711> (USP 
35, 2012b). The instrument was mechanically calibrated 
using a paddle and baskets, according to the USP 
requirements. An Agilent liquid chromatograph (Agilent 
1200 Series) equipped with a binary pump, auto-sampler 
and UV variable wavelength detector was employed in the 
quantifications of dissolved oxycodone.
Dissolution test
The tests were conducted using 900 mL of simulated 
gastric fluid (without enzymes) maintained at 37.0 ± 0.5 ºC, 
using USP baskets at a rotation speed of 100 rpm. Aliquots 
of dissolution medium were withdrawn after 1, 2, 4, 8 
and 12 hours of dissolution. Samples were filtered using 
0.45 mm syringe filters, being their oxycodone content then 
analyzed by liquid chromatography.
The liquid chromatograph was equipped with a 
230 nm detector and a 3.9 mm x 30 cm column containing 
10 mm packing L1. It was maintained at a temperature of 
60 ºC with a flow rate of about 1.0 mL per minute. Aliquots 
of 50 mL of oxycodone reference standard and sample 
solutions were injected into the chromatograph, having the 
amounts of dissolved oxycodone been calculated taking 
the areas obtained in the chromatograms as a basis (USP 
35, 2012c).
Statistical analysis
The two one-sided test was employed as an 
equivalence test to compare the results of the dissolution 
profiles of reference generic products. Equivalence was 
tested by the determination of 90% confidence intervals 
(90% CI) based on the standard deviations obtained from 
the results of each time-point of the dissolution profiles. 
In this two one-sided test, we considered a = 0.05. We 
rejected the null hypothesis and declared the dissolution 
profiles similar (or equivalent) when the 90% CI for 
the difference was completely contained in the defined 
range that was considered to be scientifically trivial (±D). 
We considered that an appropriate range to equivalence 
testing should be defined taking the specifications of the 
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dissolution test of extended-release dosage forms as a 
basis.
RESULTS AND DISCUSSION
The dissolution profile of oxycodone extended-
release tablets containing 40 mg, 20 mg and 10 mg is 
shown in Figure 1. All the evaluated products comply with 
the acceptance criteria  ̶ shown in Table I  ̶ described in the 
United States Pharmacopeia (USP 35). 
The two one-sided equivalence test showed that 
in all time-points evaluated the generic and reference 
products were found similar (Figure 2). According to the 
comparison results among doses, the two one-sided test 
showed that for some point-times there is not similarity 
(Figure 3). In the comparison between 10 mg and 40 mg 
generics we verified that the dissolution rates were not 
similar in 4 and 8hours. The same happened in the point-
times of 8 and 12 hours when comparing 10 mg and 
20 mg generics. These results are in accordance with the 
similarity factor (f2) obtained in each comparison, as 
shown in Table II.
The similarity factors (f2) obtained for the 
comparisons between generic 10 mg and generic 20 mg 
and between generic 10 mg and generic 40 mg reached a 
score above 52.6 and 55.3, respectively. In spite of this, 
these values were significantly lower than those obtained 
in the other comparisons, what might be a hint that the two 
one-sided test (TOST) is more rigorous (conservative) than 
the similarity factor (f2).
The two one-sided test (TOST) allowed us to 
identify the time-point (or time-points) that did not show 
similarity, what may help in the development of new 
products. This information is mistaken in the conventional 
similarity factor (f2) approach. One of the most important 
issues regarding the two one-sided test (TOST) is the 
definition of D. This acceptance criteria (±D) is the limit 
beyond which the difference in mean values should be 
considered scientifically significant. Its definition requires 
prior knowledge as well as its intended application. We 
TABLE I - Dissolution results of oxycodone extended-release tablets
    
Dose 
(mg)
Time 
(h)
Acceptance Criteria 
(%)
Generic 
Mean (%) (RSD %)
Reference 
Mean (%) (RSD %)
40 1 37-57 45.5 (2.8) 45.6 (3.3)
2 --- 60.1 (2.9) 59.8 (3.1)
4 68-88 77.1 (3.2) 76.2 (2.6)
8 --- 94.6 (3.5) 92.9 (1.7)
12 NLT 85 101.0 (3.4) 98.7 (1.3)
20 1 33-53 44.1 (1.4) 45.8 (1.7)
2 --- 57.8 (1.5) 59.7 (1.5)
4 63-83 74.4 (1.6) 76.7 (1.5)
8 --- 93.4 (2.0) 94.8 (1.2)
12 NLT 85 102.9 (2.6) 101.0 (1.1)
10 1 29-49 39.5 (1.1%) 38.7 (1.5)
2 --- 51.6 (1.4) 50.8 (1.7)
4 58-78 66.4 (1.4) 65.6 (1.8)
8 --- 84.0 (1.1) 83.1 (1.4)
12 NLT 85 93.4 (1.2) 91.7 (1.8)
NLT: Not less than
FIGURE 1 - Dissolution profiles for generic 10 mg (), generic 
20 mg (), generic 40 mg (), reference 10 mg (), reference 
20 mg () and reference 40 mg () products.
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FIGURE 2- Equivalence test (two one-sided test) for dissolution 
profiles of 10 mg generic versus reference 10 mg (a), 20 mg 
generic versus reference 20 mg (b) and 40 mg generic versus 
reference 40 mg (c). Dissolution time-point of 1 (), 2 (), 
4 (), 8 () and 12 hours ().
FIGURE 3 - Equivalence test (two one-sided test) for dissolution 
profiles of 10 mg generic versus 40 mg generic (a), 20 mg 
generic versus 40 mg generic (b) and 10 mg generic versus 20 
mg generic (c). Dissolution time-point of 1 (), 2 (), 4 (), 
8 () and 12 hours ().
TABLE II - Results of similarity factor (f2) and two one-sided test (TOST) for dissolution profile comparison of oxycodone extended-
release tablets
Comparisons Similarity factor (f2) Two one-sided test (TOST)
Generic 10 mg vs Reference 10 mg 91.8 Similar
Generic 20 mg vs Reference 20 mg 83.5 Similar
Generic 40 mg vs Reference 40 mg 88.8 Similar
Generic 10 mg vs Generic 40 mg 52.6 Not similar*
Generic 20 mg vs Generic 40 mg 82.9 Similar
Generic 10 mg vs Generic 20 mg 55.3 Not similar**
*No similarity in 4 and 8 hours for D = 10. **No similarity in 8 and 12 hours for D = 10.
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defined D = 10 as an appropriate range to equivalence 
testing, based on the specifications of the dissolution test 
of extended-release dosage forms.
CONCLUSION
The two one - sided equivalency test (TOST) is a 
simple and alternative approach to compare dissolution 
profiles of extended-release dosage forms. It allows us 
to identify the time-point (or time-points) that did not 
show similarity. We concluded that the two one-sided test 
performed at a significance level of 5% and defined as 
D = 10 presents results comparable to those obtained by 
the conventional similarity factor (f2).
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